Literature DB >> 18837095

Expression of livin and vascular endothelial growth factor in different clinical stages of human esophageal carcinoma.

Li Chen1, Guo-Sheng Ren, Fan Li, Shan-Quan Sun.   

Abstract

AIM: To investigate the role of livin and vascular endothelial growth factor (VEGF) in human esophageal carcinoma, and analyze its relationship to clinical stages.
METHODS: Expression of livin in fresh esophageal cancer tissues was detected by immunohistochemistry (IHC), Western blotting and reverse transcriptase-polymerase chain reaction (RT-PCR), and VEGF by Western blotting and RT-PCR. All statistical analyses were performed by SPSS version 11.0.
RESULTS: Livin positivity was also significantly correlated with tumor stages, increasing with tumor progression. Expression of livin and VEGF increased with the process of esophageal carcinoma. In the fourth clinical stage, expression of livin and VEGF was the most significant. Expression of Livin was positively correlated with VEGF.
CONCLUSION: Over-expression of livin and VEGF contributes to the pathogenesis of esophageal carcinoma.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18837095      PMCID: PMC2748213          DOI: 10.3748/wjg.14.5749

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  31 in total

Review 1.  Livin/ML-IAP as a new target for cancer treatment.

Authors:  Bin Liu; Mei Han; Jin-Kun Wen; Ling Wang
Journal:  Cancer Lett       Date:  2007-01-10       Impact factor: 8.679

2.  Expression and prognostic significance of Livin in the progression of bladder cancer.

Authors:  Zhaohui Zhu; Yanbo Wang; Xiaobo Ding; Fuqing Zeng; Kai Xu
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2008-02

3.  Overexpression of vascular endothelial growth factor 189 in breast cancer cells leads to delayed tumor uptake with dilated intratumoral vessels.

Authors:  Marie-Astrid Hervé; Hélène Buteau-Lozano; Roger Vassy; Ivan Bieche; Guillaume Velasco; Marika Pla; Gérard Perret; Samia Mourah; Martine Perrot-Applanat
Journal:  Am J Pathol       Date:  2007-12-13       Impact factor: 4.307

4.  Clinical and biological significance of vascular endothelial growth factor in endometrial cancer.

Authors:  Aparna A Kamat; William M Merritt; Donna Coffey; Yvonne G Lin; Pooja R Patel; Russell Broaddus; Elizabeth Nugent; Liz Y Han; Charles N Landen; Whitney A Spannuth; Chunhua Lu; Robert L Coleman; David M Gershenson; Anil K Sood
Journal:  Clin Cancer Res       Date:  2007-12-15       Impact factor: 12.531

Review 5.  [Renal cell carcinoma and antiangiogenic therapies].

Authors:  Damien Pouessel; Stéphane Culine; Gregory Verhoest; Jean-Jacques Patard
Journal:  Presse Med       Date:  2007-11-26       Impact factor: 1.228

6.  Expression of vascular endothelial growth factors-C and -D correlate with evidence of lymphangiogenesis and angiogenesis in pancreatic adenocarcinoma.

Authors:  Bo Zhang; Wen-Hua Zhao; Wu-Yuan Zhou; Wen-Sheng Yu; Jin-Ming Yu; Sheng Li
Journal:  Cancer Detect Prev       Date:  2007

7.  Livin may serve as a marker for prognosis of bladder cancer relapse and a target of bladder cancer treatment.

Authors:  Hai-Bo Liu; Chui-Ze Kong; Yu Zeng; Xian-Kui Liu; Jian-Bin Bi; Yuan-Jun Jiang; Sheng Han
Journal:  Urol Oncol       Date:  2008-06-16       Impact factor: 3.498

8.  Livin and Bcl-2 expression in high-grade osteosarcoma.

Authors:  T Nedelcu; B Kubista; A Koller; I Sulzbacher; I Mosberger; F Arrich; K Trieb; R Kotz; C D Toma
Journal:  J Cancer Res Clin Oncol       Date:  2007-07-14       Impact factor: 4.553

9.  Vascular endothelial growth factor immunostaining correlates with postoperative relapse and survival in non-small cell lung cancer.

Authors:  Aydin Yilmaz; Dilek Ernam; Ebru Unsal; Funda Demirag; Sükran Atikcan; Irfan Taştepe
Journal:  Arch Med Res       Date:  2007-07-12       Impact factor: 2.235

10.  Expression of inhibitor of apoptosis protein Livin in renal cell carcinoma and non-tumorous adult kidney.

Authors:  N Wagener; I Crnković-Mertens; C Vetter; S Macher-Göppinger; J Bedke; E F Gröne; H Zentgraf; M Pritsch; K Hoppe-Seyler; S Buse; A Haferkamp; F Autschbach; M Hohenfellner; F Hoppe-Seyler
Journal:  Br J Cancer       Date:  2007-10-30       Impact factor: 7.640

View more
  6 in total

1.  Expression of livin, survivin and caspase-3 in prostatic cancer and their clinical significance.

Authors:  Junfei Gu; Lixin Ren; Xiaolu Wang; Changbao Qu; Yong Zhang
Journal:  Int J Clin Exp Pathol       Date:  2015-11-01

2.  The expression of LC-3 is related to tumor suppression through angiogenesis in esophageal cancer.

Authors:  Toshihide Sakurai; Hiroshi Okumura; Masataka Matsumoto; Yasuto Uchikado; Tetsuro Setoyama; Itaru Omoto; Tetsuhiro Owaki; Kosei Maemura; Sumiya Ishigami; Shoji Natsugoe
Journal:  Med Oncol       Date:  2013-10-13       Impact factor: 3.064

Review 3.  Mesenchymal Stem Cells from Adipose Tissue in Clinical Applications for Dermatological Indications and Skin Aging.

Authors:  Meenakshi Gaur; Marek Dobke; Victoria V Lunyak
Journal:  Int J Mol Sci       Date:  2017-01-20       Impact factor: 5.923

Review 4.  Overcoming chemotherapy drug resistance by targeting inhibitors of apoptosis proteins (IAPs).

Authors:  Rama Rathore; Jennifer E McCallum; Elizabeth Varghese; Ana-Maria Florea; Dietrich Büsselberg
Journal:  Apoptosis       Date:  2017-07       Impact factor: 4.677

5.  Expression of Livin and PlGF in human osteosarcoma is associated with tumor progression and clinical outcome.

Authors:  Kuo Sun; Qi Liao; Zenggan Chen; Tongyi Chen; Jian Zhang
Journal:  Oncol Lett       Date:  2018-07-31       Impact factor: 2.967

6.  Expression and clinical significance of livin protein in hepatocellular carcinoma.

Authors:  Hua Guo; Ying-tang Gao; Qin Zhang; Li Jing; Tong Liu; Wen-xia Shi; Dao-kuan Zhai; Xiang Jing; Zhi Du
Journal:  Dis Markers       Date:  2013-10-03       Impact factor: 3.434

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.